[CAS NO. 50-70-4] D-Sorbitol
PRODUCTS SPECIFICATIONS [50-70-4]
DESCRIPTION [50-70-4]
Overview
| MDL | MFCD00004708 |
|---|---|
| Molecular Weight | 182.17 |
| Molecular Formula | C6H14O6 |
| SMILES | OC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O |
Summary
D-Sorbitol (Sorbitol) is a six-carbon sugar alcohol and can used as a sugar substitute. D-Sorbitol can be used as a stabilizing excipient and/or isotonicity agent, sweetener, humectant, thickener and dietary supplement [1] .
IC50 & Target
|
Microbial Metabolite |
Human Endogenous Metabolite |
In Vitro
Chemically, D-Sorbitol (Sorbitol) can be produced from glucose or sucrose, by hydrogenation at high temperature. D-Sorbitol (Sorbitol) can also be produced by bacteria such as
Zymomonas mobilis
and
Candida boidini
, by an enzymatic process
[1]
.
D-Sorbitol (Sorbitol) is used as a fast disintegrant in capsules and plasticizer in capsule shells and tablet film coatings. In oral liquids, D-Sorbitol (Sorbitol) is used as a sugar substitute and as a drug stabilizer. D-Sorbitol (Sorbitol) is also used as a solubility enhancer for drugs such as indomethacin. D-Sorbitol (Sorbitol) is commonly used as a stabilizing excipient and/or isotonicity agent in both liquid and lyophilized parenteral protein formulations. D-Sorbitol (Sorbitol) is used in topical formulations as a humectant
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01062633 | University of Tartu|University of Turku |
Dental Caries
|
January 2008 | Phase 2|Phase 3 |
| NCT04573153 | ScandiBio Therapeutics AB|Istanbul Medipol University Hospital|Istanbul Umraniye Training and Research Hospital|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Dr. Lutfi Kirdar Kartal Training and Research Hospital|Bagcilar Training and Research Hospital|Kanuni Sultan Suleyman Training and Research Hospital|Alanya Alaaddin Keykubat University Alanya Training and Research Hospital|Canakkale 18 Mart University Health Research and Application Hospital|Monitor CRO |
COVID-19
|
September 21, 2020 | Phase 2|Phase 3 |
| NCT00374881 | BioLineRx, Ltd. |
Acute Pain
|
September 2006 | Phase 1|Phase 2 |
| NCT05320094 | Bristol-Myers Squibb |
Healthy Participants
|
April 15, 2022 | Phase 1 |
| NCT04044131 | Istanbul Medipol University Hospital|ScandiBio Therapeutics AB|Alanya Alaaddin Keykubat University|Sahlgrenska University Hospital, Sweden|KTH Royal Institute of Technology |
Alzheimer Disease|Parkinson Disease
|
December 2, 2019 | Phase 2 |
| NCT03636971 | Brigitte Jolles, MD|University of Lausanne Hospitals |
Gait|Knee Osteoarthritis|Injection
|
May 1, 2013 | Phase 2|Phase 3 |
| NCT04955678 | Zeria Pharmaceutical |
Hyperkalemia
|
August 3, 2021 | Phase 3 |
| NCT02545712 | Bispebjerg Hospital|Rigshospitalet, Denmark |
Excipient Exposure|Neonatal|Pediatric
|
January 2016 | |
| NCT04762758 | Pharnext SA|Worldwide Clinical Trials |
Charcot-Marie-Tooth Disease
|
March 30, 2021 | Phase 3 |
| NCT03272295 | British American Tobacco (Investments) Limited|Philip Morris Products S.A.|Imperial Brands PLC|Japan Tobacco Inc.|Korea Ginseng Corporation |
Healthy Volunteers|Smoking
|
September 12, 2017 | Not Applicable |
| NCT00638677 | University of Turku|Chr Hansen|Fennobon oy, Karkkila, Finland (provides the tablets for the pacifier)|Plastone Oy, Konnevesi, Finland (provides the pacifiers) |
Dental Caries|Infectious Diseases
|
June 2004 | Phase 4 |
| NCT03747679 | Pfizer |
CML
|
November 22, 2018 | Phase 1 |
| NCT04971837 | Colorado State University |
Metabolism|Liver Function|Pharmacokinetics
|
May 20, 2021 | Not Applicable |
| NCT04330326 | ScandiBio Therapeutics AB|Koç University|Koç University Hospital|Göteborg University|Sahlgrenska University Hospital, Sweden|KTH Royal Institute of Technology|University of Helsinki|Helsinki University Central Hospital|Monitor CRO |
Non-alcoholic Fatty Liver Disease (NAFLD)
|
July 20, 2019 | Phase 2 |
| NCT05450458 | Hospital Regional Tlalnepantla |
Overuse Injury
|
July 1, 2022 | Phase 2|Phase 3 |
| NCT02634073 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
January 1, 2016 | Phase 4 |
| NCT03668015 | The University of The West Indies|J. Craig Venter Institute |
Human Microbiome
|
March 5, 2015 | Not Applicable |
| NCT01474499 | Ferring Pharmaceuticals |
Constipation
|
September 2011 | Phase 3 |
| NCT01528969 | Kuwait University|University of Turku|University of Michigan |
Bacterial Infections
|
March 2012 | Phase 1|Phase 2 |
| NCT01879605 | Oslo University Hospital |
Constipation|Ileus|Surgery
|
December 2007 | Phase 4 |
Appearance
Solid
Source
Bacillus subtilis
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 100 mg/mL ( 548.94 mM ; Need ultrasonic)
DMSO : 100 mg/mL ( 548.94 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 110 mg/mL (603.83 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution
Synonyms